If this is your first visit, be sure to check out the FAQ by clicking the link above. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. |
|
|
Thread Tools | Display Modes |
#1
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
Rate of Drug Uptake Impacts Likelihood of Abuse
FORT WASHINGTON, Pa., Oct. 27 /PRNewswire/ -- Results of a new study found that an extended-release form of methylphenidate -- sold as CONCERTA® (methylphenidate HCl in the OROS® delivery system) may be associated with a lower likelihood of abuse than immediate-release methylphenidate (sold as Ritalin®). The findings were presented today at a meeting of child and adolescent psychiatrists. "The abuse of prescription stimulant medications is a growing concern among physicians who prescribe these medications to treat Attention Deficit Hyperactivity Disorder (ADHD) and parents of children and teens who rely on these treatments to restore normal function," said Edward Sellers, MD, PhD, an investigator on this study and Professor of Pharmacology, Medicine and Psychiatry at the University of Toronto. "Our study suggests that slowing the rate of drug delivery through the extended-release OROS® technology may decrease the likelihood of abuse." The study, which evaluated 49 healthy adults with a history of light (occasional) recreational stimulant use, measured likeability using multiple scales which measured abuse-related effects, including Addiction Research Center Inventory, Drug Rating Questionnaire and Subjective Drug Value Procedure. These scales measured positive (liking or enjoyment), negative (dysphoric or disliking) and stimulant (related to reinforcement) effects. The study found that immediate-release methylphenidate produced greater subjective abuse-related effects than placebo and CONCERTA®. In addition, a therapeutic dose of CONCERTA® (54 mg) was similar to placebo on most abuse-related measures tested. Overall, the study suggests that CONCERTA® is less likely to produce abuse-related subjective effects, such as "highs" or "euphoria", possibly due to a slower and extended rate of release of methylphenidate. CONCERTA® has a unique formulation utilizing the OROS® technology that makes it less easily abused than other formulations of methylphenidate without compromising the effectiveness of the medication. The formulation of CONCERTA® is difficult to convert to an abusable form of methylphenidate. Under normal circumstances, the CONCERTA® tablet is difficult to crush, and the methylphenidate, the active ingredient in the CONCERTA® tablet, is difficult to extract. Recently, the U.S. Department of Health and Human Services' Substance Abuse and Mental Health Services Administration (SAMHSA) invited McNeil Pediatrics to discuss data on the abuse profile of CONCERTA® as part of an information exchange session titled "Progress in Creating New Drug Formulations that Discourage Tampering and Abuse." Patrick E. Ciccone, M.D., Vice President of Medical Affairs at McNeil Pediatrics, presented data to support the low likelihood of abusing CONCERTA® due to its compromise-resistant formulation and gradual rate of absorption. Additionally, a study recently published in the American Journal of Psychiatry in March 2006 concluded that CONCERTA® may be less likely to be abused than immediate-release methylphenidate drugs. Study participants taking therapeutic oral doses of CONCERTA® did not report perceiving and enjoying the drug's subjective effects, features that are associated with a medication's potential for abuse. For more information about CONCERTA®, including full U.S. prescribing information, please visit http://www.concerta.net/ , call 1-888-440-7903 or contact your healthcare provider. Important Safety Information CONCERTA® should not be taken by patients with: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients in CONCERTA®; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome. Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if your child has had problems with alcohol or drugs, has had depression, abnormal thoughts or visions, bipolar disorder, seizures, high blood pressure or has had any heart problems or defects. If your child develops abnormal thinking or hallucinations, abnormal, extreme moods and/or excessive activity, or if aggressive behavior or hostility develops or worsens while taking CONCERTA®, consult your healthcare professional. The most common adverse events reported in children receiving up to 54 mg were headache, upper respiratory tract infection and abdominal pain. The most common adverse events reported by adolescents receiving up to 72 mg were headache, accidental injury and insomnia. About McNeil Pediatrics McNeil Pediatrics Division of McNeil-PPC, Inc. is committed to meeting the needs of pediatric medicine through the development of therapies specifically formulated for children. Its leading pediatric product, CONCERTA® (methylphenidate HCl) Extended-release Tablets, is a once-a-day treatment for Attention Deficit Hyperactivity Disorder (ADHD) that uniquely combines methylphenidate with an exclusive OROS® delivery system. CONCERTA® is the number one ADHD prescribed medication in the U.S. for children and adolescents. The company is continuing to explore other new therapies to meet the special needs of children and the pediatric community. Adderall® is a registered trademark of companies within the Shire group. Ritalin® is a registered trademark of Novartis Pharmaceuticals Corp. -------------------------------------------------------------------------------- Source: McNeil Pediatrics ~~~~~~~~~~~` What they don't tell. http://www.add-adhd-help-center.com/concerta_review.htm |
#2
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
"Jan Drew" wrote in message . .. ... Source: McNeil Pediatrics I think this says a lot about the reliability of this press release. Jeff |
#3
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
"Jeff" wrote in message link.net... "Jan Drew" wrote in message . .. ... Source: McNeil Pediatrics I think this says a lot about the reliability of this press release. Jeff So you think Concerta has many side effects. |
#4
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
Jeff wrote:
"Jan Drew" wrote in message . .. ... Source: McNeil Pediatrics I think this says a lot about the reliability of this press release. Perhaps. However, the reported findings, i.e., that the method of ingestion of a substance, determines its "addictability" is quite consistent with the extensive research conducted by Nora Volkow, et al at State University of New York at Stony Brook and at Brookhaven National Laboratories. Her team found that oral administration of MPH did not have the same physiological effect on the brain as snorting the same amount of the medication. Nora Volkow is now the head of the National Institute of Drug Abuse, but remains an active researcher in the field of the physiology of addiction. |
#5
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
"Mark Probert" wrote in message news:77o1h.1762$Gg5.551@trndny02... Jeff wrote: "Jan Drew" wrote in message . .. ... Source: McNeil Pediatrics I think this says a lot about the reliability of this press release. Perhaps. However, the reported findings, i.e., that the method of ingestion of a substance, determines its "addictability" is quite consistent with the extensive research conducted by Nora Volkow, et al at State University of New York at Stony Brook and at Brookhaven National Laboratories. Her team found that oral administration of MPH did not have the same physiological effect on the brain as snorting the same amount of the medication. Nora Volkow is now the head of the National Institute of Drug Abuse, but remains an active researcher in the field of the physiology of addiction. Correct, However, I am wondering if the differences found between Ritalin and Concerta are functionally importnat. I mean, how much addictive potential does Ritalin have when taken as directed? THere is a slow release form of Ritalin (Ritalin SR), but I have never seen it advertised as a way to reduce drug addiction. Jeff |
#6
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
Poor Markey is once again posting to a thread by *me*. What happened to
your UDP? "Mark Probert" wrote in message news:77o1h.1762$Gg5.551@trndny02... Jeff wrote: "Jan Drew" wrote in message . .. ... Source: McNeil Pediatrics I think this says a lot about the reliability of this press release. Perhaps. However, the reported findings, i.e., that the method of ingestion of a substance, determines its "addictability" is quite consistent with the extensive research conducted by Nora Volkow, et al at State University of New York at Stony Brook and at Brookhaven National Laboratories. Her team found that oral administration of MPH did not have the same physiological effect on the brain as snorting the same amount of the medication. Nora Volkow is now the head of the National Institute of Drug Abuse, but remains an active researcher in the field of the physiology of addiction. Nora D. Volkow, M.D http://www.aidsaction.org/communicat...005/070805.htm This Week in Washington 1. Senator John Breaux and American University Kick Off "Ceasefire on Healthcare" Wednesday, June 29, marked the kickoff of a discussion series on health care presented by American University's Center for Congressional and Presidential Studies and featuring former Senator John Breaux (D-LA). Funded by a grant from Pfizer, Inc., the series will take place in venues around the country as part of the "Ceasefire on Health Care" Campaign. According to a media advisory issued by the campaign, the campaign aims to "put party difference aside and focus on bipartisan solutions to the health care problems facing our country." It "will examine important health care issues such as access to health care, rising costs, and uninsured Americans." 2. Congressional Briefing on Crystal Methamphetamine On Tuesday, June 28, Friends of NIDA (National Institute on Drug Abuse), in conjunction with the Congressional Caucus to Fight and Control Methamphetamine, sponsored a briefing for congressional staff, entitled Methamphetamine Addiction: Cause for Concern - Hope for the Future. (The National Institutes of Health, National Institute on Drug Abuse defines methamphetamine as "an addictive stimulant drug that strongly activates certain systems in the brain.") The speakers at the briefing we Nora Volkow, MD http://www.scienceblog.com/community...B/nih1995.html The National Institute on Drug Abuse (NIDA), National Institutes of Health, today announced it has awarded 10 grants to study the relationship between chronic stress, repeated stressors, and brain mechanisms that affect drug-use behaviors. The grants total $7.6 million over a period of 5 years. "Stress can alter a person's physiology and contribute to the development of such illnesses as hypertension, diabetes, and addiction," says Dr. Nora D. Volkow Rate of Drug Uptake Impacts Likelihood of Abuse FORT WASHINGTON, Pa., Oct. 27 /PRNewswire/ -- Results of a new study found that an extended-release form of methylphenidate -- sold as CONCERTA® (methylphenidate HCl in the OROS® delivery system) may be associated with a lower likelihood of abuse than immediate-release methylphenidate (sold as Ritalin®). The findings were presented today at a meeting of child and adolescent psychiatrists. "The abuse of prescription stimulant medications is a growing concern among physicians who prescribe these medications to treat Attention Deficit Hyperactivity Disorder (ADHD) and parents of children and teens who rely on these treatments to restore normal function," said Edward Sellers, MD, PhD, an investigator on this study and Professor of Pharmacology, Medicine and Psychiatry at the University of Toronto. "Our study suggests that slowing the rate of drug delivery through the extended-release OROS® technology may decrease the likelihood of abuse." The study, which evaluated 49 healthy adults with a history of light (occasional) recreational stimulant use, measured likeability using multiple scales which measured abuse-related effects, including Addiction Research Center Inventory, Drug Rating Questionnaire and Subjective Drug Value Procedure. These scales measured positive (liking or enjoyment), negative (dysphoric or disliking) and stimulant (related to reinforcement) effects. The study found that immediate-release methylphenidate produced greater subjective abuse-related effects than placebo and CONCERTA®. In addition, a therapeutic dose of CONCERTA® (54 mg) was similar to placebo on most abuse-related measures tested. Overall, the study suggests that CONCERTA® is less likely to produce abuse-related subjective effects, such as "highs" or "euphoria", possibly due to a slower and extended rate of release of methylphenidate. CONCERTA® has a unique formulation utilizing the OROS® technology that makes it less easily abused than other formulations of methylphenidate without compromising the effectiveness of the medication. The formulation of CONCERTA® is difficult to convert to an abusable form of methylphenidate. Under normal circumstances, the CONCERTA® tablet is difficult to crush, and the methylphenidate, the active ingredient in the CONCERTA® tablet, is difficult to extract. Recently, the U.S. Department of Health and Human Services' Substance Abuse and Mental Health Services Administration (SAMHSA) invited McNeil Pediatrics to discuss data on the abuse profile of CONCERTA® as part of an information exchange session titled "Progress in Creating New Drug Formulations that Discourage Tampering and Abuse." Patrick E. Ciccone, M.D., Vice President of Medical Affairs at McNeil Pediatrics, presented data to support the low likelihood of abusing CONCERTA® due to its compromise-resistant formulation and gradual rate of absorption. Additionally, a study recently published in the American Journal of Psychiatry in March 2006 concluded that CONCERTA® may be less likely to be abused than immediate-release methylphenidate drugs. Study participants taking therapeutic oral doses of CONCERTA® did not report perceiving and enjoying the drug's subjective effects, features that are associated with a medication's potential for abuse. For more information about CONCERTA®, including full U.S. prescribing information, please visit http://www.concerta.net/ , call 1-888-440-7903 or contact your healthcare provider. Important Safety Information CONCERTA® should not be taken by patients with: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients in CONCERTA®; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome. Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if your child has had problems with alcohol or drugs, has had depression, abnormal thoughts or visions, bipolar disorder, seizures, high blood pressure or has had any heart problems or defects. If your child develops abnormal thinking or hallucinations, abnormal, extreme moods and/or excessive activity, or if aggressive behavior or hostility develops or worsens while taking CONCERTA®, consult your healthcare professional. The most common adverse events reported in children receiving up to 54 mg were headache, upper respiratory tract infection and abdominal pain. The most common adverse events reported by adolescents receiving up to 72 mg were headache, accidental injury and insomnia. About McNeil Pediatrics McNeil Pediatrics Division of McNeil-PPC, Inc. is committed to meeting the needs of pediatric medicine through the development of therapies specifically formulated for children. Its leading pediatric product, CONCERTA® (methylphenidate HCl) Extended-release Tablets, is a once-a-day treatment for Attention Deficit Hyperactivity Disorder (ADHD) that uniquely combines methylphenidate with an exclusive OROS® delivery system. CONCERTA® is the number one ADHD prescribed medication in the U.S. for children and adolescents. The company is continuing to explore other new therapies to meet the special needs of children and the pediatric community. Adderall® is a registered trademark of companies within the Shire group. Ritalin® is a registered trademark of Novartis Pharmaceuticals Corp. -------------------------------------------------------------------------------- Source: McNeil Pediatrics ~~~~~~~~~~~` What they don't tell. http://www.add-adhd-help-center.com/concerta_review.htm |
#7
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
"Jan Drew" wrote in message ... Poor Markey is once again posting to a thread by *me*. What happened to your UDP? "Mark Probert" wrote in message news:77o1h.1762$Gg5.551@trndny02... Jeff wrote: "Jan Drew" wrote in message . .. ... Source: McNeil Pediatrics I think this says a lot about the reliability of this press release. Perhaps. However, the reported findings, i.e., that the method of ingestion of a substance, determines its "addictability" is quite consistent with the extensive research conducted by Nora Volkow, et al at State University of New York at Stony Brook and at Brookhaven National Laboratories. Her team found that oral administration of MPH did not have the same physiological effect on the brain as snorting the same amount of the medication. Nora Volkow is now the head of the National Institute of Drug Abuse, but remains an active researcher in the field of the physiology of addiction. Nora D. Volkow, M.D http://www.aidsaction.org/communicat...005/070805.htm This Week in Washington 1. Senator John Breaux and American University Kick Off "Ceasefire on Healthcare" Wednesday, June 29, marked the kickoff of a discussion series on health care presented by American University's Center for Congressional and Presidential Studies and featuring former Senator John Breaux (D-LA). Funded by a grant from Pfizer, Inc., the series will take place in venues around the country as part of the "Ceasefire on Health Care" Campaign. According to a media advisory issued by the campaign, the campaign aims to "put party difference aside and focus on bipartisan solutions to the health care problems facing our country." It "will examine important health care issues such as access to health care, rising costs, and uninsured Americans." 2. Congressional Briefing on Crystal Methamphetamine On Tuesday, June 28, Friends of NIDA (National Institute on Drug Abuse), in conjunction with the Congressional Caucus to Fight and Control Methamphetamine, sponsored a briefing for congressional staff, entitled Methamphetamine Addiction: Cause for Concern - Hope for the Future. (The National Institutes of Health, National Institute on Drug Abuse defines methamphetamine as "an addictive stimulant drug that strongly activates certain systems in the brain.") The speakers at the briefing we Nora Volkow, MD http://www.scienceblog.com/community...B/nih1995.html The National Institute on Drug Abuse (NIDA), National Institutes of Health, today announced it has awarded 10 grants to study the relationship between chronic stress, repeated stressors, and brain mechanisms that affect drug-use behaviors. The grants total $7.6 million over a period of 5 years. "Stress can alter a person's physiology and contribute to the development of such illnesses as hypertension, diabetes, and addiction," says Dr. Nora D. Volkow Rate of Drug Uptake Impacts Likelihood of Abuse FORT WASHINGTON, Pa., Oct. 27 /PRNewswire/ -- Results of a new study found that an extended-release form of methylphenidate -- sold as CONCERTA® (methylphenidate HCl in the OROS® delivery system) may be associated with a lower likelihood of abuse than immediate-release methylphenidate (sold as Ritalin®). The findings were presented today at a meeting of child and adolescent psychiatrists. "The abuse of prescription stimulant medications is a growing concern among physicians who prescribe these medications to treat Attention Deficit Hyperactivity Disorder (ADHD) and parents of children and teens who rely on these treatments to restore normal function," said Edward Sellers, MD, PhD, an investigator on this study and Professor of Pharmacology, Medicine and Psychiatry at the University of Toronto. "Our study suggests that slowing the rate of drug delivery through the extended-release OROS® technology may decrease the likelihood of abuse." The study, which evaluated 49 healthy adults with a history of light (occasional) recreational stimulant use, measured likeability using multiple scales which measured abuse-related effects, including Addiction Research Center Inventory, Drug Rating Questionnaire and Subjective Drug Value Procedure. These scales measured positive (liking or enjoyment), negative (dysphoric or disliking) and stimulant (related to reinforcement) effects. The study found that immediate-release methylphenidate produced greater subjective abuse-related effects than placebo and CONCERTA®. In addition, a therapeutic dose of CONCERTA® (54 mg) was similar to placebo on most abuse-related measures tested. Overall, the study suggests that CONCERTA® is less likely to produce abuse-related subjective effects, such as "highs" or "euphoria", possibly due to a slower and extended rate of release of methylphenidate. CONCERTA® has a unique formulation utilizing the OROS® technology that makes it less easily abused than other formulations of methylphenidate without compromising the effectiveness of the medication. The formulation of CONCERTA® is difficult to convert to an abusable form of methylphenidate. Under normal circumstances, the CONCERTA® tablet is difficult to crush, and the methylphenidate, the active ingredient in the CONCERTA® tablet, is difficult to extract. Recently, the U.S. Department of Health and Human Services' Substance Abuse and Mental Health Services Administration (SAMHSA) invited McNeil Pediatrics to discuss data on the abuse profile of CONCERTA® as part of an information exchange session titled "Progress in Creating New Drug Formulations that Discourage Tampering and Abuse." Patrick E. Ciccone, M.D., Vice President of Medical Affairs at McNeil Pediatrics, presented data to support the low likelihood of abusing CONCERTA® due to its compromise-resistant formulation and gradual rate of absorption. Additionally, a study recently published in the American Journal of Psychiatry in March 2006 concluded that CONCERTA® may be less likely to be abused than immediate-release methylphenidate drugs. Study participants taking therapeutic oral doses of CONCERTA® did not report perceiving and enjoying the drug's subjective effects, features that are associated with a medication's potential for abuse. For more information about CONCERTA®, including full U.S. prescribing information, please visit http://www.concerta.net/ , call 1-888-440-7903 or contact your healthcare provider. Important Safety Information CONCERTA® should not be taken by patients with: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients in CONCERTA®; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome. Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if your child has had problems with alcohol or drugs, has had depression, abnormal thoughts or visions, bipolar disorder, seizures, high blood pressure or has had any heart problems or defects. If your child develops abnormal thinking or hallucinations, abnormal, extreme moods and/or excessive activity, or if aggressive behavior or hostility develops or worsens while taking CONCERTA®, consult your healthcare professional. The most common adverse events reported in children receiving up to 54 mg were headache, upper respiratory tract infection and abdominal pain. The most common adverse events reported by adolescents receiving up to 72 mg were headache, accidental injury and insomnia. About McNeil Pediatrics McNeil Pediatrics Division of McNeil-PPC, Inc. is committed to meeting the needs of pediatric medicine through the development of therapies specifically formulated for children. Its leading pediatric product, CONCERTA® (methylphenidate HCl) Extended-release Tablets, is a once-a-day treatment for Attention Deficit Hyperactivity Disorder (ADHD) that uniquely combines methylphenidate with an exclusive OROS® delivery system. CONCERTA® is the number one ADHD prescribed medication in the U.S. for children and adolescents. The company is continuing to explore other new therapies to meet the special needs of children and the pediatric community. Adderall® is a registered trademark of companies within the Shire group. Ritalin® is a registered trademark of Novartis Pharmaceuticals Corp. -------------------------------------------------------------------------------- Source: McNeil Pediatrics ~~~~~~~~~~~` What they don't tell. http://www.add-adhd-help-center.com/concerta_review.htm oncerta Review - Unexpected Psychiatric Reactions in Children. The FDA, after a Concerta review, plans to strengthen warnings about the possible psychiatric side effects of Concerta and similar drug treatments for ADHD. A routine FDA review of Concerta found that there have been dozens of reports of hallucinations, violence, thoughts of suicide and death. Yes, death. The FDA found 16 deaths from Concerta since the popular drug was first introduced five years ago. Some doctors have been quoted as saying that parents should not overreact to this report. But, if you are the parents of any one of those 16 children who died from taking the drug, you would absolutely argue that point. The FDA website on Wednesday, June 29, 2005 listed the top 20 reported Concerta complaints found in its Concerta review. Below is a list of side effects currently not listed on the Concerta warning label: a.. Aggression b.. Abnormal behavior c.. Agitation d.. Hallucination e.. Anxiety f.. Depression g.. Suicide ideation (thoughts of suicide) h.. Completed suicide i.. Confusional state j.. Disorientation k.. Chest pain Heart complications have also been found in addition to these unexpected psychiatric reactions in children. Concerta, a once-daily form of methylphenidate (Ritalin), is now the most prescribed drug for ADHD. A subsequent review of other methylphenidate products found similar psychiatric complications. The FDA plans to conduct a review of Adderall and Strattera to see whether similar behavior is reported with these ADHD drug treatments. That review is expected to be complete early in 2006. Adderall has already been linked to at least 20 deaths. In 2004 the FDA required that Shire Pharmaceutical Group, the makers of Adderall, provide doctors with warning about sudden cardiovascular death linked to Adderall. Canadian officials in February 2005 ordered Adderall off the market in Canada after reports of sudden deaths related to the drug. Johnson & Johnson, the maker of Concerta, declined to comment on the FDA Concerta review. It is natural for parents to question whether taking a powerful stimulant like Concerta is in their child's best interests. Stimulants like Concerta are worrisome for many reasons - predominately because of the potential for harmful Concerta side effects. Most doctors believe the side effects of Concerta, and all ADHD medication, should be carefully weighed against the benefits before prescribing potentially harmful ADHD medication like Ritalin, Adderall, Concerta. Since Concerta does not cure ADHD, but only temporarily controls symptoms, a growing number of health professionals and parents alike now look to alternatives to ADHD medication to address the causes of Attention Deficit and hyperactivity. The more holistic and health-based physicians will often recommend supplements and lifestyle changes to diminish the symptoms of Attention Deficit Disorder and hyperactivity. If you are concerned about the health effects of Concerta, or other ADHD medications, closely review Attend as a safe and effective alternative to drugs. There are healthful and effective ways of dealing with Attention Deficit Disorder, with seizure disorders and with depression that do not include the use of high-powered medications. |
#8
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
Jan Drew wrote:
"Jan Drew" wrote in message ... Poor Markey is once again posting to a thread by *me*. What happened to your UDP? "Mark Probert" wrote in message news:77o1h.1762$Gg5.551@trndny02... Jeff wrote: "Jan Drew" wrote in message . .. ... Source: McNeil Pediatrics I think this says a lot about the reliability of this press release. Perhaps. However, the reported findings, i.e., that the method of ingestion of a substance, determines its "addictability" is quite consistent with the extensive research conducted by Nora Volkow, et al at State University of New York at Stony Brook and at Brookhaven National Laboratories. Her team found that oral administration of MPH did not have the same physiological effect on the brain as snorting the same amount of the medication. Nora Volkow is now the head of the National Institute of Drug Abuse, but remains an active researcher in the field of the physiology of addiction. Nora D. Volkow, M.D http://www.aidsaction.org/communicat...005/070805.htm This Week in Washington 1. Senator John Breaux and American University Kick Off "Ceasefire on Healthcare" Wednesday, June 29, marked the kickoff of a discussion series on health care presented by American University's Center for Congressional and Presidential Studies and featuring former Senator John Breaux (D-LA). Funded by a grant from Pfizer, Inc., the series will take place in venues around the country as part of the "Ceasefire on Health Care" Campaign. According to a media advisory issued by the campaign, the campaign aims to "put party difference aside and focus on bipartisan solutions to the health care problems facing our country." It "will examine important health care issues such as access to health care, rising costs, and uninsured Americans." 2. Congressional Briefing on Crystal Methamphetamine On Tuesday, June 28, Friends of NIDA (National Institute on Drug Abuse), in conjunction with the Congressional Caucus to Fight and Control Methamphetamine, sponsored a briefing for congressional staff, entitled Methamphetamine Addiction: Cause for Concern - Hope for the Future. (The National Institutes of Health, National Institute on Drug Abuse defines methamphetamine as "an addictive stimulant drug that strongly activates certain systems in the brain.") The speakers at the briefing we Nora Volkow, MD http://www.scienceblog.com/community...B/nih1995.html The National Institute on Drug Abuse (NIDA), National Institutes of Health, today announced it has awarded 10 grants to study the relationship between chronic stress, repeated stressors, and brain mechanisms that affect drug-use behaviors. The grants total $7.6 million over a period of 5 years. "Stress can alter a person's physiology and contribute to the development of such illnesses as hypertension, diabetes, and addiction," says Dr. Nora D. Volkow Rate of Drug Uptake Impacts Likelihood of Abuse FORT WASHINGTON, Pa., Oct. 27 /PRNewswire/ -- Results of a new study found that an extended-release form of methylphenidate -- sold as CONCERTA® (methylphenidate HCl in the OROS® delivery system) may be associated with a lower likelihood of abuse than immediate-release methylphenidate (sold as Ritalin®). The findings were presented today at a meeting of child and adolescent psychiatrists. "The abuse of prescription stimulant medications is a growing concern among physicians who prescribe these medications to treat Attention Deficit Hyperactivity Disorder (ADHD) and parents of children and teens who rely on these treatments to restore normal function," said Edward Sellers, MD, PhD, an investigator on this study and Professor of Pharmacology, Medicine and Psychiatry at the University of Toronto. "Our study suggests that slowing the rate of drug delivery through the extended-release OROS® technology may decrease the likelihood of abuse." The study, which evaluated 49 healthy adults with a history of light (occasional) recreational stimulant use, measured likeability using multiple scales which measured abuse-related effects, including Addiction Research Center Inventory, Drug Rating Questionnaire and Subjective Drug Value Procedure. These scales measured positive (liking or enjoyment), negative (dysphoric or disliking) and stimulant (related to reinforcement) effects. The study found that immediate-release methylphenidate produced greater subjective abuse-related effects than placebo and CONCERTA®. In addition, a therapeutic dose of CONCERTA® (54 mg) was similar to placebo on most abuse-related measures tested. Overall, the study suggests that CONCERTA® is less likely to produce abuse-related subjective effects, such as "highs" or "euphoria", possibly due to a slower and extended rate of release of methylphenidate. CONCERTA® has a unique formulation utilizing the OROS® technology that makes it less easily abused than other formulations of methylphenidate without compromising the effectiveness of the medication. The formulation of CONCERTA® is difficult to convert to an abusable form of methylphenidate. Under normal circumstances, the CONCERTA® tablet is difficult to crush, and the methylphenidate, the active ingredient in the CONCERTA® tablet, is difficult to extract. Recently, the U.S. Department of Health and Human Services' Substance Abuse and Mental Health Services Administration (SAMHSA) invited McNeil Pediatrics to discuss data on the abuse profile of CONCERTA® as part of an information exchange session titled "Progress in Creating New Drug Formulations that Discourage Tampering and Abuse." Patrick E. Ciccone, M.D., Vice President of Medical Affairs at McNeil Pediatrics, presented data to support the low likelihood of abusing CONCERTA® due to its compromise-resistant formulation and gradual rate of absorption. Additionally, a study recently published in the American Journal of Psychiatry in March 2006 concluded that CONCERTA® may be less likely to be abused than immediate-release methylphenidate drugs. Study participants taking therapeutic oral doses of CONCERTA® did not report perceiving and enjoying the drug's subjective effects, features that are associated with a medication's potential for abuse. For more information about CONCERTA®, including full U.S. prescribing information, please visit http://www.concerta.net/ , call 1-888-440-7903 or contact your healthcare provider. Important Safety Information CONCERTA® should not be taken by patients with: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients in CONCERTA®; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome. Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if your child has had problems with alcohol or drugs, has had depression, abnormal thoughts or visions, bipolar disorder, seizures, high blood pressure or has had any heart problems or defects. If your child develops abnormal thinking or hallucinations, abnormal, extreme moods and/or excessive activity, or if aggressive behavior or hostility develops or worsens while taking CONCERTA®, consult your healthcare professional. The most common adverse events reported in children receiving up to 54 mg were headache, upper respiratory tract infection and abdominal pain. The most common adverse events reported by adolescents receiving up to 72 mg were headache, accidental injury and insomnia. About McNeil Pediatrics McNeil Pediatrics Division of McNeil-PPC, Inc. is committed to meeting the needs of pediatric medicine through the development of therapies specifically formulated for children. Its leading pediatric product, CONCERTA® (methylphenidate HCl) Extended-release Tablets, is a once-a-day treatment for Attention Deficit Hyperactivity Disorder (ADHD) that uniquely combines methylphenidate with an exclusive OROS® delivery system. CONCERTA® is the number one ADHD prescribed medication in the U.S. for children and adolescents. The company is continuing to explore other new therapies to meet the special needs of children and the pediatric community. Adderall® is a registered trademark of companies within the Shire group. Ritalin® is a registered trademark of Novartis Pharmaceuticals Corp. -------------------------------------------------------------------------------- Source: McNeil Pediatrics ~~~~~~~~~~~` What they don't tell. http://www.add-adhd-help-center.com/concerta_review.htm oncerta Review - Unexpected Psychiatric Reactions in Children. The FDA, after a Concerta review, plans to strengthen warnings about the possible psychiatric side effects of Concerta and similar drug treatments for ADHD. A routine FDA review of Concerta found that there have been dozens of reports of hallucinations, violence, thoughts of suicide and death. Yes, death. The FDA found 16 deaths from Concerta since the popular drug was first introduced five years ago. Some doctors have been quoted as saying that parents should not overreact to this report. But, if you are the parents of any one of those 16 children who died from taking the drug, you would absolutely argue that point. The FDA website on Wednesday, June 29, 2005 listed the top 20 reported Concerta complaints found in its Concerta review. Below is a list of side effects currently not listed on the Concerta warning label: a.. Aggression b.. Abnormal behavior c.. Agitation d.. Hallucination e.. Anxiety f.. Depression g.. Suicide ideation (thoughts of suicide) h.. Completed suicide i.. Confusional state j.. Disorientation k.. Chest pain Heart complications have also been found in addition to these unexpected psychiatric reactions in children. Concerta, a once-daily form of methylphenidate (Ritalin), is now the most prescribed drug for ADHD. A subsequent review of other methylphenidate products found similar psychiatric complications. The FDA plans to conduct a review of Adderall and Strattera to see whether similar behavior is reported with these ADHD drug treatments. That review is expected to be complete early in 2006. Adderall has already been linked to at least 20 deaths. In 2004 the FDA required that Shire Pharmaceutical Group, the makers of Adderall, provide doctors with warning about sudden cardiovascular death linked to Adderall. Canadian officials in February 2005 ordered Adderall off the market in Canada after reports of sudden deaths related to the drug. Johnson & Johnson, the maker of Concerta, declined to comment on the FDA Concerta review. It is natural for parents to question whether taking a powerful stimulant like Concerta is in their child's best interests. Stimulants like Concerta are worrisome for many reasons - predominately because of the potential for harmful Concerta side effects. Most doctors believe the side effects of Concerta, and all ADHD medication, should be carefully weighed against the benefits before prescribing potentially harmful ADHD medication like Ritalin, Adderall, Concerta. Since Concerta does not cure ADHD, but only temporarily controls symptoms, a growing number of health professionals and parents alike now look to alternatives to ADHD medication to address the causes of Attention Deficit and hyperactivity. The more holistic and health-based physicians will often recommend supplements and lifestyle changes to diminish the symptoms of Attention Deficit Disorder and hyperactivity. If you are concerned about the health effects of Concerta, or other ADHD medications, closely review Attend as a safe and effective alternative to drugs. There are healthful and effective ways of dealing with Attention Deficit Disorder, with seizure disorders and with depression that do not include the use of high-powered medications. yep, these are powerful drugs, and they're not perfect. yet, they've provided relief to many people who otherwise would be suffering far worse. nothing in life if perfect. expecting it from pharmaceuticals is unrealistic. |
#9
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
Jeff wrote:
"Mark Probert" wrote in message news:77o1h.1762$Gg5.551@trndny02... Jeff wrote: "Jan Drew" wrote in message . .. ... Source: McNeil Pediatrics I think this says a lot about the reliability of this press release. Perhaps. However, the reported findings, i.e., that the method of ingestion of a substance, determines its "addictability" is quite consistent with the extensive research conducted by Nora Volkow, et al at State University of New York at Stony Brook and at Brookhaven National Laboratories. Her team found that oral administration of MPH did not have the same physiological effect on the brain as snorting the same amount of the medication. Nora Volkow is now the head of the National Institute of Drug Abuse, but remains an active researcher in the field of the physiology of addiction. Correct, However, I am wondering if the differences found between Ritalin and Concerta are functionally importnat. I mean, how much addictive potential does Ritalin have when taken as directed? For a decade, I have asked anyone and everyone who claims that methylphenidate is addictive to provide proof that it is addictive if taken as prescribed. No one has taken up the request. During that period I have not sat on my hands waiting. I have RSS feeds from PubMed which is "methylphenidate AND addiction" and several variants. No case studies reported. THere is a slow release form of Ritalin (Ritalin SR), but I have never seen it advertised as a way to reduce drug addiction. There have been some studies/reports of the use of MPH to treat cocaine addiction. I do not have the references handy. |
#10
|
|||
|
|||
Rate of Drug Uptake Impacts Likelihood of Abuse
"Jeff" wrote in message k.net... "Mark Probert" wrote in message news:77o1h.1762$Gg5.551@trndny02... Jeff wrote: "Jan Drew" wrote in message . .. ... Source: McNeil Pediatrics I think this says a lot about the reliability of this press release. Perhaps. However, the reported findings, i.e., that the method of ingestion of a substance, determines its "addictability" is quite consistent with the extensive research conducted by Nora Volkow, et al at State University of New York at Stony Brook and at Brookhaven National Laboratories. Her team found that oral administration of MPH did not have the same physiological effect on the brain as snorting the same amount of the medication. Nora Volkow is now the head of the National Institute of Drug Abuse, but remains an active researcher in the field of the physiology of addiction. Correct, However, I am wondering if the differences found between Ritalin and Concerta are functionally importnat. I mean, how much addictive potential does Ritalin have when taken as directed? THere is a slow release form of Ritalin (Ritalin SR), but I have never seen it advertised as a way to reduce drug addiction. I think the major difference is that it is harder to snort one than the other--I have heard stories of people doing that with ritalin, but so far have not heard the same about concerta--unless someone has come up with a way around the new technology... -- Buny " Nobody realizes that some people expend tremendous energy merely to be normal." ~ Albert Camus |
Thread Tools | |
Display Modes | |
|
|
Similar Threads | ||||
Thread | Thread Starter | Forum | Replies | Last Post |
Smack ban 'breaking up families' | MoJo Werkin | Spanking | 20 | July 27th 06 10:46 PM |
A School Paddling Correlation Study | [email protected] | Foster Parents | 2 | November 9th 05 01:48 PM |
WDNNSCPS was Child Abuse is A Crime | [email protected] | Foster Parents | 42 | September 18th 05 07:03 AM |
Spanking is Violence in the Netherlands now. | Kane | Spanking | 23 | March 23rd 05 01:21 AM |
| | Kids should work... | Kane | General | 13 | December 10th 03 02:30 AM |